Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Cash from Financing Activities (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Cash from Financing Activities data on record, last reported at $248000.0 in Q4 2023.

  • For Q4 2023, Cash from Financing Activities rose 100.75% year-over-year to $248000.0; the TTM value through Dec 2023 reached $40.8 million, up 257.14%, while the annual FY2025 figure was $1.1 million, 99.59% down from the prior year.
  • Cash from Financing Activities reached $248000.0 in Q4 2023 per CGEM's latest filing, up from $112000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $264.6 million in Q1 2021 and bottomed at -$32.9 million in Q4 2022.
  • Average Cash from Financing Activities over 4 years is $28.2 million, with a median of $1.8 million recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: tumbled 1318.06% in 2022, then surged 1817.64% in 2023.
  • A 4-year view of Cash from Financing Activities shows it stood at $124.9 million in 2020, then plummeted by 97.84% to $2.7 million in 2021, then crashed by 1318.06% to -$32.9 million in 2022, then skyrocketed by 100.75% to $248000.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $248000.0 in Q4 2023, $112000.0 in Q3 2023, and $38.6 million in Q2 2023.